Androgen Deprivation Therapy News and Research

RSS

Higher radiation doses over shorter periods of time for prostate cancer doesn't lead to sexual dysfunction

Recent advances in the delivery of radiation therapy for prostate cancer are fueling a new trend of providing higher radiation doses over shorter periods of time.

29 Oct 2007

New research may show why some prostate cancer recurs after treatment

Cancer researchers have long worked to understand why some prostate cancers recur after the use of therapies designed to stop the production of testosterone and other androgens that fuel cancer cell growth.

12 Oct 2007

Androgen deprivation therapy linked to increased risk of heart disease death

The use of androgen deprivation therapy to treat localized prostate cancer is associated with an increased risk of death from heart disease, according to a study published online October 9 in the Journal of the National Cancer Institute .

10 Oct 2007

Prostate cancer treatment may encourage spread of cancer cells

According to a new study by researchers in the U.S. the popular prostate cancer treatment, androgen deprivation therapy, may in fact encourage the spread of cancer cells throughout the body.

3 Oct 2007

Androgen deprivation therapy for prostate cancer may encourage spread of disease

A popular prostate cancer treatment called androgen deprivation therapy may encourage prostate cancer cells to produce a protein that makes them more likely to spread throughout the body, a new study by Johns Hopkins researchers suggests.

1 Oct 2007

Treatment for early prostate cancer associated with type of specialist seen

A new study analyzing men with localized prostate cancer shows that the specialty of the physician they see can influence the type of therapy they ultimately receive.

5 Jun 2007

Gabapentin reduces hot flashes in men receiving androgen deprivation therapy

North Central Cancer Treatment Group ( http://ncctg/ ) researchers based at Mayo Clinic ( http://www.mayo.edu/ ) in Rochester, Minn., have discovered that low doses of a drug used to prevent epileptic seizures and to treat nerve pain caused by shingles substantially reduces hot flashes in patients who are undergoing anti-hormonal treatment, or androgen-deprivation therapy, for prostate cancer.

5 Jun 2007

Calcium intake could be used as a prognostic factor for osteoporosis

Measuring a man's daily calcium intake is an effective way of identifying prostate cancer patients with a higher than average risk of osteoporosis, according to the April issue of the urology journal BJU International.

11 Apr 2007

Research shows relationship between low calcium intake and higher levels of osteoporosis in men with prostate cancer

Daily calcium intake is an effective way of identifying prostate cancer patients with a higher than average risk of osteoporosis, according to the April issue of the urology journal BJU International.

11 Apr 2007

Obesity at the time of prostate-cancer diagnosis dramatically increases the risk of dying from the disease

Obese men who are diagnosed with prostate cancer have more than two-and-a-half times the risk of dying from the disease as compared to men of normal weight at the time of diagnosis, according to a study by researchers at Fred Hutchinson Cancer Research Center.

15 Mar 2007

Androgen deprivation therapy may increase risk of death from heart disease in older men

Androgen deprivation therapy - one of the most common treatments for prostate cancer - may increase the risk of death from heart disease in patients over age 65, according to a new study by researchers at Dana-Farber Cancer Institute, Brigham and Women's Hospital and other institutions.

26 Feb 2007

New research could affect future treatment options for prostate cancer

Two new studies on the treatment of prostate cancer could well affect future treatment options for patients.

8 Nov 2006

Long-term oncologic outcomes: A 40 year radical prostatectomy single institution series

Single institution long-term outcomes for radical prostatectomy are scarce in the literature. In the August 2006 issue of the Journal of Urology, Dr. Porter from the Virginia Mason Medical Center, Seattle, WA reports on 25-year cancer outcomes for radical prostatectomy (RP).

6 Sep 2006

Biomira Stimuvax prostate cancer study results published

Biomira Inc. has announced publication of study results showing that Stimuvax, formerly known as BLP25 Liposome Vaccine or L-BLP25, could slow rising Prostate Specific Antigen (PSA) levels in some post-surgical prostate cancer patients

20 Jul 2006

Usage and outcomes of primary androgen deprivation therapy for localized prostate cancer

In the online March 2006 version of Cancer, Dr. Kawakami and associates report from the CaPSURE database that primary androgen deprivation therapy (PADT) is used in 14% of prostate cancer (CaP) patients with reasonable outcomes at approximately 5 years follow-up.

11 Apr 2006

$Hormone therapy for advanced prostate cancer can lead to bone loss and fractures$

Hormone therapy for advanced prostate cancer can lead to bone loss and fractures

A common type of treatment used to protect bone density in menopausal women is also an effective therapy for advanced prostate cancer patients during the first year of hormone therapy, according to a new Oregon Health & Science University Cancer Institute study.

1 Mar 2006

Oral agent alendronate may help men with prostate cancer suffering from bone loss

Men with prostate cancer who experience bone loss from cancer treatment could benefit from a weekly oral therapy commonly given to women with osteoporosis, according to a study presented by the University of Pittsburgh Medical Center (UPMC) at the American Society of Clinical Oncology Prostate Cancer Symposium, Feb. 24 to 26 at the San Francisco Marriott.

27 Feb 2006

Androgen deprivation therapy does not prevent prostate cancer from spreading

Oregon Health & Science University Cancer Institute researchers wanted to know if depriving men of testosterone actually keeps cancer from spreading beyond the prostate.

27 Feb 2006

Researchers identify biomarker that indicates a more agressive form of prostate cancer

Staging factors for prostate cancer such as PSA and the Gleason score are extremely useful in predicting prostate cancer outcome," explained Pollack. "However, new biomarkers hold promise in strengthening our ability to predict response to treatment. By identifying the more virulent forms of prostate cancer, we may be able to tailor treatment or develop therapies to target the abnormalities identified."

17 Oct 2005

Hormone therapy for prostate cancer can affect men's thinking

Androgen-deprivation therapy (AD), an effective therapy in the treatment of prostate cancer reduces levels of testosterone (a tumor stimulant), and estradiol, a form of estrogen, in men. These are known to be important in neurological development and play a particularly important role in the cognitive areas of learning and memory.

28 Feb 2005